Summary by Moomoo AI
Biodexa Pharmaceuticals, a clinical-stage biopharmaceutical company, reported a consolidated loss of £7.08 million for the year ended December 31, 2023, with negative cash flows from operating activities amounting to £6.83 million. The company's financial performance reflects the significant investment in research and development as it advances its portfolio, including its lead assets tolimidone for Type 1 diabetes and MTX110 for rare/orphan brain cancers. Revenue for the year was £381,000, a decrease from the previous year's £699,000. The company's financial statements have been prepared under the assumption that it will continue as a going concern, despite the recurring losses and net capital deficiency raising substantial doubt about this ability. Biodexa Pharmaceuticals' strategy focuses on developing clinical-stage assets to proof-of-concept before seeking...Show More